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Abstract
Background: The Hepatitis B Virus (HBV) HBx regulatory protein is required for HBV replication and involved in HBV-
related carcinogenesis. HBx interacts with chromatin modifying enzymes and transcription factors to modulate histone
post-translational modifications and to regulate viral cccDNA transcription and cellular gene expression. Aiming to
identify genes and non-coding RNAs (ncRNAs) directly targeted by HBx, we performed a chromatin
immunoprecipitation sequencing (ChIP-Seq) to analyse HBV recruitment on host cell chromatin in cells replicating HBV.
Results: ChIP-Seq high throughput sequencing of HBx-bound fragments was used to obtain a high-resolution,
unbiased, mapping of HBx binding sites across the genome in HBV replicating cells. Protein-coding genes and ncRNAs
involved in cell metabolism, chromatin dynamics and cancer were enriched among HBx targets together with genes/
ncRNAs known to modulate HBV replication. The direct transcriptional activation of genes/miRNAs that potentiate
endocytosis (Ras-related in brain (RAB) GTPase family) and autophagy (autophagy related (ATG) genes, beclin-1, miR-
33a) and the transcriptional repression of microRNAs (miR-138, miR-224, miR-576, miR-596) that directly target the HBV
pgRNA and would inhibit HBV replication, contribute to HBx-mediated increase of HBV replication.
Conclusions: Our ChIP-Seq analysis of HBx genome wide chromatin recruitment defined the repertoire of genes and
ncRNAs directly targeted by HBx and led to the identification of new mechanisms by which HBx positively regulates
cccDNA transcription and HBV replication.
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Background
Despite the availability of an effective prophylactic vac-
cine and potent antiviral therapies hepatitis B virus
(HBV) is still a major health problem. Over 240 million
people chronic hepatitis B virus (HBV) carriers world-
wide remain at risk of developing hepatocellular carcin-
oma (HCC) [1, 2]. The persistence of viral replication
in the liver and high serum HBV-DNA levels correlate
with disease severity, progression of liver fibrosis and
HCC development in the clinical setting [2].
The HBV regulatory protein HBx is both required
for HBV replication [3] and implicated in HBV-related
oncogenesis [4]. The mechanisms underlying the
pleiotropic activities of HBx have been only partially
elucidated. HBx regulates transcription both directly,
at the chromatin level, and indirectly, by affecting
intracellular signaling pathways that modulate the ac-
tivity of multiple transcription factors [4]. HBx has
been shown to target the epigenetic control of cellular
genes expression by interacting with chromatin modi-
fying enzymes [5–7]. HBx is also recruited to the
cccDNA in HBV-infected cells [3] and is required for
the transcription of all viral RNAs from the cccDNA
minichromosome in the nucleus [3, 8]. HBx is thought
to regulate cccDNA transcription by two main mecha-
nisms: a) the degradation of the Smc5/6 restriction
factor mediated by the DDB1 – Cul4 E3 ligase com-
plex [9, 10] and b) the prevention of cccDNA epigen-
etic silencing by the histone deacetilase HDAC1 [8],
the protein arginine N-methyltransferase 1 (PRMT1)
[11], the Tudor-domain protein Spindlin-1 [12] and
the histone methyl-transferase SETDB1 [13, 14].
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Additional HBx activities that boost HBV replication
are DNA Methyltransferase 3 Alpha (DNMT3A)
downregulation mediated by miR-101 induction [15],
the elevation of cytosolic calcium levels [16] and the
induction of autophagy [17].
Results
ChIP-Seq analysis of genome wide HBx recruitment
To obtain a high-resolution, unbiased, mapping of HBx
binding sites across the genome we sequenced HBx-bound
fragments by ChIP-Seq in a cccDNA-driven HBV replica-
tion system [18]. Four independent anti-HBx paired ChIPs
were carried out on formaldehyde-crosslinked chromatin
from mock and HBV-transfected HepG2 cells. On average,
~62% of the reads could be aligned to the hg19 version of
the human genome (Additional file 1: Figure S1a); ~1% of
the total number of reads aligned to the HBV genome (ayw
strain, NCBI Reference Sequence: NC_003977.2) and ~1%
of reads falls on the mitochondrial genome. All reads with
multiple alignments and mismatches with the reference ge-
nomes were excluded (~6.3% with at least one unknown
base, ~11% with multiple alignment and ~13% with 1 or 2
mismatches). ~4000 statistically significant peaks/run (P-
value < 10−4) were detected. About 12% of the HBx peaks
were located within 10kb from the transcription start site
(TSS) of known genes, 44.6% were located in intergenic re-
gions and 39.5% within introns (Additional file 1: Figure
S1b-S1c).
Functional analysis of the genes potentially regulated by
HBx
We first performed a functional enrichment analysis of
the whole genome repertoire of the genes potentially regu-
lated by HBx in HBV replicating HepG2 cells. Figure 1a
shows the categories enriched, respectively, among the
KEGG and Reactome Biological Pathways; the Gene Ontol-
ogy (GO) Biological Processes and the InterPro families, a
database that integrates diverse information about protein
Fig. 1 Functional analysis of protein-coding genes potentially regulated by HBx. a Biological Pathways (KEGG, REACTOME), Biological Processes
(GO) and Protein families, domains and important sites (InterPro) over-represented (Benjamini-corrected p-value < 5×10−2) from the analysis of
~5500 protein-coding genes with HBx-binding sites are shown. In each plot, the categories are in descending order with respect to the associ-
ated gene number, with the corresponding color scale of p-values shown on the right. b Validation of HBx occupancy on selected gene pro-
moters in independent ChIP experiments. ChIP results are expressed as Fold Induction (FI) of the % of Input. Histograms show the mean from
three independent experiments; bars indicate SD. P-values: * 0,02≤ P < 0,05; ** 0,01≤ P < 0.02; *** 0,005≤ P < 0.01. Gene specific promoter primer
pairs are detailed in Additional file 1: Table S6
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families, domains and functional sites. Overall, the results
show a significant enrichment in genes involved in cell
metabolism, chromatin dynamics and cancer, but also in
biological pathways that have been associated with the
control of HBV replication [i.e. Ras/Src [19], calcium
transport, endocytosis]. It is important to underline that,
since the HBx ChIP-Seq dataset was generated in HBV
replicating HepG2 cells, which are derived from a primary
liver tumor, and that an enrichment in genes belonging to
the metabolism, chromatin dynamics and cancer pathways
is often found in many immortalized and transformed cell
lines, a number of the HBx genomic binding sites we
found might reflect a bias for transcriptionally active chro-
matin regions in the “tumor cell” chromatin environment.
Independent anti-HBx ChIP experiments confirmed HBx
recruitment, with a 3 to 8-fold enrichment relative to the
control IgG ChIPed samples, to the promoter regions of se-
lected genes belonging to different functional categories
[Hsa04144: Rab1A, Rab2B, Rab5B; GO:0006357: SREBP2,
Beclin1; Has04010: Traf2; Hsa05200: Stat1; IPR013032:
Lama3; GO:0045892: Dnmt3B] in HBV replicating HepG2
cells (Fig. 1b) and in HBV-infected NTCP-HepG2 cells
(Additional file 1: Figure S2a) and primary human hepato-
cytes from 2 different donors (Additional file 1: Figure S2b).
Validated PCR primers for genomic target sites that
were negative for anti-HBx ChIP-Seq peak assignment
showed no enrichment in the HBx immunoprecipitated
chromatin, thus confirming the lack of off-target HBx
recruitment and the specificity of the anti-HBx ChIP
(Additional file 1: Figure S3).
HBx directly enhances endocytosis
The enrichment of genes involved in endocytosis among
HBx targets (Fig. 1a) represents a potential link between
its role in viral replication [20, 21] and its contribution to
liver cancer development [22]. Our ChIP-Seq analysis
showed that HBx is recruited and potentially regulates 24
members of the Ras-related in brain (RAB) GTPase family
of genes, including several RAB GTPases implicated in
endocytosis (Additional file 1: Table S1). HBx binding to
the RAB1A, RAB2B and RAB5B promoter regions (see
Fig. 1b) was accompanied by an increase in promoter-
bound histone H4 acetylation (Fig. 2a) and RAB1A,
RAB2B and RAB5B expression (Fig. 2b) in HBV-wt repli-
cating cells but not in HBx-mt replicating cells. The up-
regulation of RAB1A, RAB2B and RAB5B expression was
confirmed in HBV-infected NTCP-HepG2 cells (Fig. 2c)
and human primary hepatocytes (PHH) (Fig. 2d). The
specificity of HBx binding to the RAB1A, RAB2B and
RAB5B promoter regions was further confirmed in
NTCP-HepG2 cells infected with HBV-wt and HBx-mt
virus (Additional file 1: Figure S4). Notably, HBV-wt
HepG2 replicating cells showed a robust uptake of trans-
ferrin, with intense perinuclear accumulation, whereas
transferrin distribution was more diffuse in mock HepG2
cells and in HBx-mt HepG2 replicating cells due to a di-
minished rate of transferrin internalization (Fig. 3).
HBx is also recruited to and potentially regulates several
genes involved in autophagy, including Beclin-1, SREBP2
and several members of the ATG (AuTophaGy related)
gene family (Additional file 1: Table S1). HBV has been
show to induce ER stress and cellular autophagy, which is
known to enhance viral replication and virions assembly
[17]. Beclin-1 is a major effector of autophagy in mamma-
lian cells and has been shown to be upregulated in HBV-
related HCCs, HBx-overexpressing cells and 2.2.15 HBV
replicating cells [23]. The SREBP-2 transcription factor,
known to be a major regulator of cholesterol metabolism,
has also been involved in the direct activation of several
genes involved in autophagy [24]. HBx recruitment to the
Beclin-1 and SREBP2/miR-33a promoter regions was con-
firmed in independent ChIP experiments performed in
HBV-wt replicating cells (Fig. 1b). HBV-wt replicating
cells, but not HBx-mt replicating cells, displayed higher
levels of histone H4 acetylation on the Beclin-1 and
SREBP2 promoters as compared to HBV mock cells
(Fig. 2a) and increased expression of Beclin-1 and SREBP2
(Fig. 2b). These results were confirmed in HBV-infected
NTCP-HepG2 cells (Fig. 2c) and HBV-infected human
primary hepatocytes (PHH) (Fig. 2d). Altogether, these re-
sults indicate that HBx targets endocytosis and autophagy
gene expression in HBV replicating cells.
ChIP-Seq identifies ncRNAs directly targeted by HBx
Analyses of the distribution of all the anti-HBx ChIP-
Seq peaks revealed the occurrence of putative HBx bind-
ing sites in 16 lncRNA promoters and 32 lncRNA intra-
genic regions, in 44 snoRNA, 3 snRNA and 75 miRNA
promoter regions (Additional file 1: Figure S1d). 39 out
of the 75 HBx targeted miRNAs are classified as intra-
genic [25] and 15 of them display HBx peaks in the pro-
moter region of their target genes. Independent anti-
HBx ChIP experiments in HBV replicating HepG2 cells
(Fig. 4a), HBV-infected NTCP-HepG2 cells (Additional
file 1: Figure S5a) and PHHs (Additional file 1: Figure
S5b) confirmed HBx binding to selected miRNA pro-
moters (>4-fold enrichment relative to the control IgG
ChIPed samples in 11 out of 13). Primers designed to
overlap an HBx peak detected with a higher P-value (P
= 1E-3) showed no enrichment in anti-HBx ChIPed
DNA (Additional file 1: Figure S6).
The 75 miRNAs targeted by HBx include several miR-
NAs that have been implicated in the regulation of specific
liver functions (n = 9), in HBV replication (n = 6), in hepato-
carcinogenesis (n = 12), cancer (n = 30) and others the func-
tion of which is not yet known (n = 40) (Additional file 1:
Table S2). The analysis of the selected miRNA promoter se-
quences bound by HBx using the Genomatix MatInspector
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resource showed the presence of binding sites for multiple
transcription factors that have been reported to interact
with HBx, including NFAT, CREB, NFkB, SREBP1, STAT,
E2F and SMAD [4], a finding consistent with a mechanism
of piggy-backing for HBx mediated by multiple transcrip-
tion factors (Additional file 1: Table S3).
Next, we analyzed the impact of HBx chromatin re-
cruitment on the expression of HBx targeted miRNAs.
Figure 4b shows the differential expression, analyzed by
real-time qPCR, of the 15 miRNAs encoded from the 13
promoters used for the independent validation of HBx
chromatin recruitment in Fig. 4a. 8 miRNAs [miR-1913,
miR-129-3p miR-129-5p, miR-26b; miR-551b-3p, miR-
551b-5p, miR-3648, miR-3687] are consistently upregu-
lated (>1.3 fold) and 5 miRNAs [miR-138, miR-224,
miR-302e, miR-576-3p, miR-596] are downregulated
(<0.7 fold) in HBV-wt HepG2 replicating cells. 4
miRNAs [miR-21, miR-26a-5p, miR-452, miR-552] are
apparently not modulated or only slightly modulated by
HBV replication in this assay (Fig. 4b). Notably, con-
cordant results were obtained for 9/13 miRNAs included
in the miRNAs Taqman microarrays profiles from HBV-
infected (12 dpi) PHHs (Fig. 4c and Additional file 1:
Figure S7). miR-21 and miR-452, that were only slightly
up-regulated 48 h after transfection in HBV-replicating
HepG2 cells, were significantly up-regulated in PHH 12
days after infection. HBV up-regulation of miR-21 ex-
pression is consistent with previous reports [26]. miR-
552 was dowregulated in HBV-wt replicating HepG2
cells at 48 h withouth reaching <0.7 fold threshold but
its levels were significantly reduced in HBV-infected
PHH. miR-596 was dowregulated 48 h after transfection
in HBV-wt replicating HepG2 cells and significantly up-
regulated in HBV-infected PHH.
Fig. 2 HBx ChIP-seq identifies direct target genes involved in endocytosis. a H4 acetylation on Rab1A, Rab2B, Rab5B, Srebp2 and Beclin 1 genes
promoters assessed in independent ChIP experiments. Anti-AcH4 ChIPed chromatin from mock, HBV-wt and HBx-mt HBV replicating HepG2 cells
and NTCP-HepG2 HBV-infected cells. Results are expressed as in Fig. 1b. b–d qPCR quantification of Rab1A, Rab2B Rab5B, Srebp2 and Beclin-1
mRNA levels in mock, HBV-wt and HBx-mt HepG2 cells replicating HBV (b) HBV-infected NTCP-HepG2 (c) and PHHs (d). Results are expressed as
fold induction relative to the mock-transfected/infected controls (Ctl) after normalization to endogenous human β-actin mRNAs. Data represent
means ± SD from at least three independent experiments performed in duplicate. P-values: * 0,02 ≤ P < 0,05; ** 0,01 ≤ P < 0.02; *** 0,005≤ P < 0.01
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HBx recruitment impacts on H4 histone acetylation of
neighboring chromatin promoters. As shown in Fig. 4d,
H4 acetylation was decreased on the promoter regions
of miR-138-2, miR-224, miR-302e, miR-576-3p and miR-
596, all repressed by HBx. Conversely, HBx recruitment
was accompanied by an increased H4 acetylation at the
miR-26b promoter (Fig. 4d), whose expression is acti-
vated in HBV-wt replicating HepG2 cells and HBV-
infected PHH (Fig. 4b and Additional file 1: Figure S5).
These results confirm the HBx ability to influence tran-
scription by directly modulating the epigenetic status of
target promoters and provide a mechanism for miRNA
repression by HBx.
A subset of HBx targeted miRNAs represses HBV
replication
A number of miRNAs directly or indirectly promote or
repress HBV replication (see ref. [27] and Additional file
1 : Table S4). Thus, miR-122 abrogates p53-mediated in-
hibition of HBV replication by targeting cyclin G1 and
its interaction with p53 [28]. miR-372/373 and miR-501
promote HBV gene expression by targeting the tran-
scription factor nuclear factor I/B [29] and HBXIP [30],
respectively. miR-1 increases HBV transcription and rep-
lication by targeting HDAC4, which in turn represses
HBV transcription [31]. miR-15b potentiates HBV repli-
cation by targeting HNF1a and relieving its repressive
activity on HBV Enhancer 1 [32]. Conversely, miR-141
suppresses HBV expression and replication in HepG2
cells by targeting PPARa [33] and mir-130a inhibits
hepatitis B virus replication by targeting PGC1α and
PPARγ [34]. miR-199a-3p and miR-210 [35], miR-15a/
miR-16-1 [36], the miR-17-92 cluster [37] and miR-1231
[38] have been shown to target HBV mRNAs directly
and to inhibit HBV replication. None of these miRNAs
showed HBx recruitment in our ChIP-Seq analysis, nei-
ther to their putative promoter sequence nor to the pro-
moter regions of their host genes, with the exception of
miR-15a and miR16.1 that are embedded into the DLeu2
lncRNA gene, the promoter of which harbors an HBx
binding peak.
We investigated whether the miRNAs repressed by HBx
binding to their regulatory regions might directly target
HBV transcripts, and in particular the HBV pgRNA. HBx
repression could relieve the miRNA-directed down-
regulation of HBV replication and unveal new miRNA–
dependent auto-regulatory loops in HBV replicating cells.
In silico analysis revealed the presence of several putative
seed sequences on the HBV genome specific for HBx-
regulated miRNAs, which are also conserved across HBV
genotypes (Additional file 1: Table S5). As shown in Fig. 5a,
pre-miR-138, pre-miR-224 and pre-miR-596 overexpression
reduces HBV pgRNA levels, whereas pre-miR-302e does
not. Similarly, pre-mir-26a2, that is not modulated by HBV
in our systems and we use as a control, did not affect HBV
pgRNA levels (Fig. 5a). Notably, co-transfection of HBV-wt
together with pre-miR-138-2, pre-miR-224, and pre-miR-
596 resulted in a significant reduction of HBV replication,
measured as cytoplasmic core particles associated rcHBV-
DNA (Fig. 5b). Altogether, these results suggest that HBx
repression of miR-138, miR-224 and miR-596 expression
relieves the negative effects of these miRNAs on HBV repli-
cation. On the other hand, mir-302e likely downregulates
HBV regulation indirectly, by targeting one or more genes
involved in the regulation of HBV replication.
In order to better characterize the interplay between
HBx, HBx-targeted miRNAs and HBV replication, we
selected miR-224, whose expression is repressed by HBV
replication (ref [39] bis and Fig. 4b and c) and increased
in HCC patients [39–42] where its expression is driven
Fig. 3 HBx directly enhances endocytosis. Endocytosis of transferrin is increased in HBV-wt replicating HepG2 cells. Representative images of Alexa
Fluor 594-conjugated human transferrin uptake (red, left panels), nuclear staining with Hoechst (blue, middle panels) and nuclear GFP positive
transfected cells (green, right panels) in mock, HBV-wt and HBx-mt HBV transduced HepG2 cells. Histograms represent the mean and SD of Alexa
488-conjugated transferrin signal quantified by ImageJ software in 100 cells from each of 3 independent experiments
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Fig. 4 (See legend on next page.)
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by the TNF/LT-NFkB signaling [42]. Alignment of ChIP-
Seq HBx occupancy on the intronic miR-224 regulatory
region revealed the presence of a NFkB/p65 consensus
motif, which is known to be a direct transcriptional
regulator of miR-224 expression and up-regulation in
human hepatocellular carcinoma [42]. HBx recruitment
is accompanied by a strong co-recruitment of p65 and
the DNMT3A DNA methyltransferase (Fig. 5c) in the
same region of the miR-224 promoter, that is accompan-
ied by an hypoacetylation of Histone 4 lysines (Fig. 4d).
We also show that exogenously expressed HBx repressed
miR-224 promoter in a transient luciferase reporter
assay (Fig. 5d). Altogether these results strongly suggest
the recruitment of HBx as part of a transcriptionally in-
active NFkB/p65 complex on the miR-224 promoter,
which is responsible for the silencing of miR-224
transcription.
Next, to confirm that the inhibition of HBV replication
by miR-224 is indeed the result of a direct targeting of
HBV 3.5Kb/pgRNA, the 5 putative seed sequences identi-
fied by the RNAhybrid software in the HBV genome
(Fig. 6a) were cloned at the 3′UTR of the Renilla Lucifer-
ase gene in the pRL-TK vector (Fig. 6b). Co-transfection
of the different Renilla Luciferase constructs together with
pre-miR-224 showed a significative inhibition of the Lucif-
erase activity for constructs containing seed 1 and seed 4,
thus confirming that HBV is a direct target of miR-224
which inhibits viral replication by directly binding HBV
genome on seed 1 and seed 4 (Fig. 6b).
Discussion
Our ChIP-Seq genome wide analysis of HBx chromatin
recruitment in HBV replicating cells provides a reper-
toire of genes and ncRNAs directly targeted by HBx and
led us to propose new mechanisms by which HBx po-
tentiates HBV replication. As already mentioned, a pos-
sible limitation of our study is that our HBx ChIP-Seq
data set was generated in HBV replicating HepG2 cells,
which are transformed cells derived from primary liver
tumor, wild type for p53 and mutated for β-catenin. In-
deed, some of the “enriched genes” are associated with
pathways, such as metabolism, chromatin dynamics and
cancer, that are often found to be deregulated in
transcriptomic analysis of immortalized and tumor cell
lines. It cannot be excluded that a number of HBx gen-
omic binding sites identified in our study might reflect a
bias for transcriptionally active chromatin regions
present in HepG2 cells. It is conceivable that the same
regions might not be transcriptionally active, and there-
fore potentially not be targeted by HBx, in normal hepa-
tocytes (i.e. a human liver recently infected by HBV or
primary human hepatocytes infected in vitro by HBV).
However, strong clinical evidence links HBV replication
with the development of HBV-related HCCs and HBx
expression has been widely implicated in HCC develop-
ment and progression. Thus, a repertoire of HBx gen-
omic binding sites identified in a tumor derived
hepatocytic cell line, such as the HepG2 cells, might be
very relevant for HBV-induced hepatocarcinogenesis.
Most HBx targets validated in our study have been con-
firmed in primary hepatocytes from different donors
and, notably, HBx is recruited very early post-infection
on the regulatory sequence of miR-21, a well established
onco-miR, also in HBV-infected primary human
hepatocytes.
We found that HBx activates several genes and miRNAs
that potentiate endocytosis and autophagy to favor HBV
replication, and represses miRNAs (miR-224, miR-138
and miR-596) that potentially target the HBV pgRNA and
would inhibit HBV replication (Fig. 7). Thus, HBx binding
to the cccDNA increases pgRNA transcription and HBV
replication and, at the same time, HBx protects the
pgRNA from the negative effects of miRNAs miR-224,
miR-138 and miR-596 by targeting their promoters and
inhibiting their expression. To better characterize the
interplay between HBx, HBx targeted miRNAs and HBV
replication we focused on miR-224. The down-regulation
of miR-224 expression in HBV replicating cells (ref [35]
and Fig. 4b and c) and HBV infected primary hepatocytes
(Additional file 1: Figure S5) is in apparent contradiction
with the reported up-regulation of miR-224 in elevated in
HCC [40–42] including HBV-related HCCs [42]. Notably,
Amaddeo et al. have reported that HBx inactivating muta-
tions, including missense/stop and frameshift mutations
as well as deletions, are selected in HBV-related HCCs
that carry a lower number of viral copies as compared to
(See figure on previous page.)
Fig. 4 ChIP-seq miRNA peak validation and HBx targeted miRNAs expression. a HBx occupancy on the putative promoter regions (−5000 + 1000
nt relative to position +1 of each miRNA in MirBase v18) of selected miRNAs (Additional file 1: Figure S1d) was validated in independent ChIP
experiments. Cross-linked chromatin from mock or HBV-wt replicating HepG2 cells was immunoprecipitated with a specific anti-HBx antibody or
relevant IgG controls, and then analyzed by real-time qPCR using specific primer pairs (see Additional file 1: Table S6). ChIP results are expressed
as Fold Induction (FI) of the % of Input and the histograms show the mean from three independent experiments; bars indicate SD. b–c miRNA
profiles were analyzed by real-time qPCR, and normalized with respect to RNU38, in mock, HBV-wt and HBx-mt replicating HepG2 cells (b) and by
Taqman PCR-arrays in HBV infected (12 dpi) PHHs (c). Data represent means ± SD from at least three independent experiments performed in du-
plicate. d HBx recruitment impacts on H4 histone acetylation of neighboring chromatin promoters. Anti-AcH4 ChIPs were performed and analysed
as in a). P-values: * 0,02≤ P < 0,05; ** 0,01 ≤ P < 0.02; *** 0,005≤ P < 0.01
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the non-tumor tissues [43]. Although it would be challen-
ging to obtain a formal demonstration in vivo, it is tempt-
ing to speculate that, in the early phases of HBV infection,
HBx binding at or near the p65/NFkB sites in the miR-
224 promoter leads to the repression of miR-224 expres-
sion, that would be detrimental for viral replication,
whereas HBx inactivation leaves the miR-224 promoter
free to respond to TNF/LT-NFkB signaling in HCCs and
highly displastic nodules.
Conclusions
The analysis of HBx genome wide chromatin recruit-
ment provides a repertoire of genes and ncRNAs directly
targeted by HBx and led to the identification of new
mechanisms by which HBx positively regulates cccDNA
transcription and HBV replication.
Methods
Cell cultures
HepG2 (ATCC HB-8065), HepG2.2.15 (a HepG2 clone
transfected with a plasmid containing two head-to-tail
dimers of the HBV genome, kindly provided by H. Will,
MPI, Martinsried, Germany) and NTCP-HepG2 (a
HepG2 clone transfected with a plasmid expressing the
HBV receptor Na+-taurocholate cotransporting polypep-
tide (NTCP), kindly provided by S Urban, Heidelberg
University, Germany) cells were cultured in supple-
mented Dulbecco’s modified Eagle’s medium (DMEM)
Fig. 5 Impact of HBx-targeted miRNAs on 3.5Kb/pgRNA transcription and HBV replication. a HepG2 cells are co-transfected with linear wild type
HBV genomes (HBV) and the indicated pre-hsa-miRNAs. HBV 3.5Kb/pgRNA levels were determined by real-time qPCR using specific primers. Re-
sults were expressed as fold induction relative to mock controls (Ctl) after normalization towards endogenous human β-actin mRNAs. b rcHBV-
DNA levels associated to cytoplasmatic core particles were determined by real-time qPCR after normalization to β-globin. Histograms represent
the mean from 3 independent experiments; bars indicate SDs. P values were determined using the Student’s t test. *P < 0.05. c DNMT3A and p65
recruitment on miR224 promoter. ChIPed chromatin from mock and HBV-wt replicating HepG2 cells. Results are expressed as in Fig. 4a. d Left
panel. Putative regulatory region (−2500/+1000 from TSS) and schematic representation of the luciferase construct containing the miR-224 pro-
moter region. The sequence was analyzed by motif software (http://www.genome.jp/tools/motif/) using a cut off score of 85%. Black diamonds
represent p53 binding sites; white circles represent NFkB consensus; white triangles represent AP1 consensus; black rectangles represent TCF/LEF
consensus and grey star represents HNF-3β consensus. Right panel. HepG2 cells were transfected with 250 ng of the −1841/+1035 miR-224 lucifer-
ase construct together with 250 ng of HBx expression vector. Luciferase activity was assayed 30h after transfection and expressed as fold induc-
tion over the control. Histograms represent the mean of 3 independent experiments each performed in duplicate; bars indicate S.D. P-values: *
0,02≤ P < 0,05; ** 0,01≤ P < 0.02; *** 0,005≤ P < 0.01
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as described [44] and maintained in a 5% CO2 humidi-
fied incubator at 37 C.
Transient transfection of full-length HBV DNA genomes
The pCR.HBV.A.EcoRI and the pCR.HBXmt.A.EcoRI
plasmids were restricted by EcoRI-PvuI (New England
Biolabs) to generate monomeric linear full-length WT
(genotype A, adw) and HBx-mt (carrying a termination
site at the codon 8 of the X ORF) HBV genomes [44]. Lin-
ear HBV monomers were transfected into HepG2 human
hepatoma cells using the Mirrus Bio transIT-LT1 (Mir
2300A). Briefly, 2–3 × 106 or 1–2 × 107 HepG2 cells are
seeded in 100-mm or 150-mm-diameter Petri dishes, re-
spectively, transfected after 24 h with 1 to 2 μg of digested
Fig. 6 Direct targeting of HBV 3.5Kb/pgRNA by miR-224. a In silico analysis of the HBV genome, performed with the RNAhybrid tool on the Biele-
feld University Bioinformatics Server, revealed the presence of several putative miR-224 seed sequences that are conserved across HBV genotypes.
b Upper panels. Schematic representation of the putative seed sequences of HBV genome cloned on the 3′ UTR of the Renilla luciferase gene in
the pRL-TK vector (Promega). Lower panels. HepG2 cells were transfected with the above indicated luciferase constructs together with 30nM of
pre-miR-224 or its relative control. Luciferase activity was assayed 30h after transfection and expressed as fold induction over the control. All histo-
grams represent the mean of three indipendent experiments each performed in duplicate; bars indicate S.D. P-values: * 0,02≤ P < 0,05; ** 0,01≤
P < 0.02; *** 0,005≤ P < 0.01. Grey stars, HBV genotype A; black stars, genotype A, C, D. c Proposed model for a differential modulation of miR-224
expression by HBx and inflammatory cytokines in ealrly phases of HBV infection and in HCC
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HBV DNA and harvested 48 h post-transfection. A GFP
expression vector (500 ng) was included to assess transfec-
tion efficiency (range 28%–32%). The HBV region span-
ning the predicted ends of the linear dsDNA was
amplified and sequenced to exclude the generation of cir-
cular HBV DNA molecules carrying sequence modifica-
tions at the recombination site. Southern blot analysis has
shown that the HBV cccDNA species in the nuclear ex-
tracts from HepG2 transfected cells co-migrate with the
cccDNA isolated from an HBV-infected liver used as a
positive control and are converted into a linear DNA by
XhoI digestion [18].
Primary culture of human hepatocytes and HBV infection
Primary human hepatocytes (PHH) (provided by Prof.
M. Rivoire) were prepared from HBV, HCV and HIV
negative adult patients undergoing lobectomy or seg-
mental liver resection for medically required purposes
unrelated to this research program. PHH were prepared
and cultured as described elsewhere [45]. Briefly, the
cells are plated overnight in collagen-coated dishes (BD
Biosciences) at 2×105 cells/cm2 in William’s medium
(Life Technologies) supplemented with 10% FetalClone
II (Thermo Scientific), 1% penicillin/streptomicine and
1% glutamine (Life Technologies), as well as 5 μg/ml In-
sulin and 5×10-7 M hydrocortisone hemisuccinate
(Sigma Aldrich). After 24 h PHH are extensively washed
in serum-free medium and kept in serum-free medium
for one more day to counter select the growth of con-
taminating fibroblast and endothelial cells, and infected
48 hours after plating with HBV virus (i.e. inoculum)
produced in HepG2.2.15 cells [46].
ChIP assays
Cells are resuspended in 0,2–0,4 ml of ChIP lysis buffer
(50 mM Tris HCL, pH 8, 0.5% NP40, 1 mM EDTA, and
100 mM NaCL), incubated 10 min at 4°C and the lysate
centrifuged at 10,000 g for 2 min. The nuclei are fixed in
1% formaldehyde for 30 min at 4°C, extracted with a 20
mM Tris, pH 8, 3 mMMgCl2, 20 mM KCl buffer contain-
ing protease inhibitors, pelleted by microcentrifugation
and lysed in SDS lysis buffer (1% sodium dodecyl sulfate,
10 mM EDTA, 50 mM Tris-chloride, pH 8.1) containing
protease inhibitors. Chromatin is sonicated using a Bior-
uptor Sonicator (Diagenode Inc) to generate 300- to 1000-
bp DNA fragments (5 pulses of 45 s at 80% power) for
ChIP and 200- to 300-bp DNA fragments (total time of 20
min, 30 s ON, 30 s OFF) for ChIP-Seq. After microcentri-
fugation, the supernatant is diluted 1:10 in dilution buffer
(0.01% sodium dodecyl sulfate, 1.1% Triton X-100, 1.2
mM EDTA, 16.7 mM Tris-chloride, pH 8.1, 167 mM
NaCl, containing protease inhibitors). 100 μl of antibody-
coupled magnetic beads (Invitrogen Dynalbeads) are
added to each 1 ml chromatin preparation and incubated
on a rotator for 14–16 h at 4°C. The antibodies used are
anti-HBx (MA1-081; mouse monoclonal IgG1), anti-
AcH4 (06–866, Upstate; rabbit polyclonal IgG recognizing
histone H4 acetylated at lysines 6, 9, 13, and 17), anti-
DNMT3A (sc-20703; Santa Cruz Biotechnology Inc.),
anti-p65 (sc-372; Santa Cruz Biotechnology Inc.). Nonspe-
cific immunoglobulins (Santa Cruz Biotechnology Inc.)
are used as negative controls. After the reverse cross-
linking, immunoprecipitated chromatin was purified by
phenol/chloroform (1:1) extraction and ethanol precipita-
tion. ChIPed chromatin is analyzed by real-time PCR
amplification using either primers (NCC1 and CCCAS)
and probes (FL and Red) specific for the HBV cccDNA [3]
or specific primers for genes and miRNAs promoters and
the SYBR Green DNA Master mix (Applied Biosystems,
Inc., Foster City, US-CA) (Additional file 1: Table S6). For
ChIP-Seq chromatin is prepared from ~2×107 cells / ex-
perimental point and processed according to the Illumina
ChIp-Seq libraries generation protocol (IP-102-1001) and
sequenced on Illumina GAII/GAIIx platforms. The eluate
was quantified by using a Qubit (Invitrogen) fluorometer.
The quality of each anti-HBx ChIP processed for ChIP-
Seq was prealably assessed by controlling HBx binding to
the HBV cccDNA [8] and to the MT1F gene promoter
[47]. DNA fragments recovered from reverse cross-linked
chromatin are repaired, ligated to adapters, size selected
and PCR-amplified to generate NGS libraries following
the Illumina DNA Library Construction Kit.
ChIP-Seq data analysis
Reads (36 bp) were mapped to the UCSC human gen-
ome hg19 using Bowtie (version 0.12.9) [48]. Uniquely
aligned reads with no mismatches were retained for
Fig. 7 Schematic representation of HBx-dependent mechanisms that
contribute to boost HBV replication
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subsequent analyses. Peak-calling was performed using
model-based analysis for ChIP-seq (MACS, version
1.4.2) [49], following the protocol described in Feng et
al. [50]. Peak-calling was performed against a refer-
ence input sample from the same HepG2 cell line.
Home-made Perl scripts (www.biocomputing.it;
“Tools” section; Scripts related to Guerrieri et al.)
were used to locate HBx candidate binding sites along
the genome, taking into account three categories: pro-
moters (10 kb upstream or 1 kb downstream the tran-
scriptional start site (TSS) of genes), intragenic (from
1 kb after TSS up to the transcript end site (TES)) and
intergenic. For microRNAs, in particular, the promoter
HBx binding sites were located within the range of
(−5000; +1000) bps relative to the TSS. All potential
target protein-coding genes were annotated according
to UCSC, RefSeq and GenCode; for non-coding genes
(snoRNAs, snRNAs and lincRNAs) we referred to the
Ensembl Annotation and for microRNAs to the miR-
Base database v18 [51].
Functional enrichment analyses of candidate HBx target
genes
All protein-coding genes with putative HBx binding sites
(promoters or intragenic) were analysed by DAVID [52]
and FIDEA [53] web servers using KEGG [54] and Reac-
tome pathways [55, 56], the InterPro families [57] and
the Gene Ontology (GO) Biological Processes [58]. Only
biological terms with Benjamini-corrected p-value < 0.05
were considered enriched.
Plasmids and luciferase assay
The miR-224 promoter region −1841/+1035 (relative to
the pre-miR sequence was amplified by PCR from HepG2
genomic DNA with the following primers: luc-miR-
224_FOR 5′-AATCCTGTGCACCTCATCCTCTGT-3′;
luc-miR-224_REV 5′-GACGAGCGGAG AAGGTTCTT-
3′. The amplified region was cloned into the pGL3 Basic
Vector (Promega, Madison, WI, USA) using the T4 DNA
ligase (Promega, Madison, WI, USA) and the construct
was confirmed by sequencing. Putative miR-224 seed se-
quences in the HBV genome (genotipe A; ADW) were
amplified by PCR with specific primers (Additional file 1:
Table S6), cloned in the 3′ UTR of the Renilla luciferase
gene in the pRL-TK vector (Promega) and confirmed by
sequencing. For luciferase assay, cells are transfected with
the indicated luciferase reporter constructs and expression
vectors using the Lipofectamine Plus reagent (Invitrogen
Inc., Carlsbad, CA, USA). Luciferase activity in cell lysates
is measured using the Luciferase Assay System (Promega,
Madison, WI, USA) 30 h after transfection and the results
normalized for protein levels (Bradford, Bio-Rad Labora-
tories, Hercules, CA, USA). Pre-miRNA-224 and anti-
miRNA-224 (Ambion #AM17100 and #AM17000) are
transfected with the Lipofectamine plus reagent (Invitro-
gen Inc., Carlsbad, CA, USA) at a final concentration of
30 nmol/l and cells were analyzed 30 h after transfection.
HBV pgRNA and cellular mRNA analysis
Total RNA was extracted using the TRIzol reagent (Invitro-
gen). RNA samples are treated with RQ1 RNase-Free
DNase (Promega) for 30 min at 37°C and RNA quality and
quantity monitored by ethidium bromide staining and UV
absorbance. For pgRNA analysis, 2 μg of DNase-treated
RNA are reverse transcribed (ThermoScript RT-PCR
System, Invitrogen) and quantified by real-time PCR ana-
lysis (Light Cycler; Roche Diagnostics) using the following
pgRNA-specific primers and probes: forward primer, 5′-




CAAC-3′. RNA samples are normalized using the
hGAPDH housekeeping gene Light Cycler Set (Roche
Diagnostics). miRNAs and mRNAs levels in cultured cells
were assayed, after reverse transcription (ThermoScript,
Invitrogen, Inc., Carlsbad, US-CA) using miRNA specific
stem-loop primers or random primers, by quantitative
qPCR using either a specific TaqMan FAM-probe (Applied
Biosystems, Inc.) with the specific primers. Results were
normalized with respetct to RNU38 or β-actin and
expressed as described above.
Taqman® array microRNA cards
Total RNA is extracted from PHH at different time points
after HBv infection with TRIzol® reagent (Life Technologies)
according to manufacturer’s instructions. The Megaplex™
RT primer human pool A + B v3.0 (Life Technologies) was
used for miRNA-specific reverse transcription. RNA quality
and quantity were monitored by ethidium-bromide staining
and by UV absorbance. The Megaplex™ RT product was
then loaded on Taqman® microRNA cards A + B and run
performed with default thermal cycling conditions (Taq-
man® array user bulletin – Life Technologies). Data were
collected through SDS 2.3 software and analyzed through
RQ Manager 1.2 program (Life Technologies).
Core-particles associated HBV DNA purification and
quantitation
Cells are washed with ice-cold PBS, lysed in 50 mmol Tris–
HCl, pH 7.4, 1 mmol EDTA, and 1% NP-40 (lysis buffer A)
and nuclei pelleted by centrifugation for 1 min at 10,000 g.
The supernatants are adjusted to 100 mmol MgCl2, treated
with 100 mg/ml of DNase I for 30 min at 37°C and then
with 0.5 mg/ml proteinase K and 1% SDS for 2 h at 50°C.
Nucleic acids are purified by phenol- chloroform (1:1) ex-
traction and ethanol precipitation adding glycogen. HBV
DNA is quantified by real-time PCR in a Light Cycler
Guerrieri et al. BMC Genomics  (2017) 18:184 Page 11 of 14
instrument (Roche) using the following primers and probes:
forward, 5′-CTCGTGGTGGACTTCTCTC-3′, and reverse
5′-CAGCAGGATGAAGAGGAA-3′. We also used spe-
cific FRET hybridization probes: 5′-CACTCACCAACCTC
CTGTCCTCCAA-FL-3′, Red640, 5′-TGTCCTGGTTAT
CGCTGGATGT GTCT-3′. Amplifications were performed
as follows: 95°C for 5 min, followed by 45 cycles at 95°C for
10 s, 58°C for 10 s, and 72°C for 20 s.
Immunofluoresence and transferrin-uptake assay
HepG2 cell lines were grown overnight on glass coverslips
in 6-well plates. The cells were serum-starved at 37 °C for
1 h in starving medium (DMEM 0%), then incubated at
37 °C for 15–20 min in starving medium containing 25
μg/ml of biotinylated holo-transferrin (Sigma T-3915).
Cells were fixed in 4% paraformaldehyde at room
temperature for 20 min, washed thrice with PBS, permea-
bilised, blocked with TBS + 0.2% Saponin + 10% serum
anti rabbit for 15 min, and then incubated at 37 °C for 1 h
with 1:500 dilution of Streptavidin from Molecular Probes
conjugated to the fluorophor Alexa 594 (Invitrogen). After
three washes with TBS + 0.02% Saponin + 1% serum, the
coverslips were mounted onto glass slides. Images of
Transferrin, DAPI and GFP-fluorescence were acquired
using a Zeiss 510 Meta confocal microscope (all images
were obtained with the same exposure setting). Alexa 594-
conjugated transferrin signal intensity was quantified for
10 transfected cells in each set, and the mean intensity cal-
culated and normalized against that of the nontransfected
cells (Mock) with the software ImageJ.
Statistics
P values were determined using the 2-tailed Student’s t test.
Wilcoxon rank-sum test was used for nonparametric pair-
wise comparisons. P < 0.05 was considered significant.
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